| Ident. | Authors (with country if any) | Title |
|---|
| 000004 (2017) |
Miguel Martin ; Frankie A. Holmes ; Bent Ejlertsen ; Suzette Delaloge ; Beverly Moy ; Hiroji Iwata ; Gunter Von Minckwitz ; Stephen K L. Chia ; Janine Mansi ; Carlos H. Barrios ; Michael Gnant ; Zorica Tomaševi ; Neelima Denduluri ; Robert Šeparovi ; Erhan Gokmen ; Anna Bashford ; Manuel Ruiz Borrego ; Sung-Bae Kim ; Erik Hugger Jakobsen ; Audrone Ciceniene ; Kenichi Inoue ; Friedrich Overkamp ; Joan B. Heijns ; Anne C. Armstrong ; John S. Link ; Anil Abraham Joy ; Richard Bryce ; Alvin Wong ; Susan Moran ; Bin Yao ; Feng Xu ; Alan Auerbach ; Marc Buyse ; Arlene Chan | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| 000238 (2017) |
Alice T. Shaw ; Enriqueta Felip ; Todd M. Bauer ; Benjamin Besse ; Alejandro Navarro ; Sophie Postel-Vinay ; Justin F. Gainor ; Melissa Johnson ; Jorg Dietrich ; Leonard P. James ; Jill S. Clancy ; Joseph Chen ; Jean-François Martini ; Antonello Abbattista ; Benjamin J. Solomon | Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. |
| 000412 (2017) |
Meletios A. Dimopoulos ; Hartmut Goldschmidt ; Ruben Niesvizky ; Douglas Joshua ; Wee-Joo Chng ; Albert Oriol ; Robert Z. Orlowski ; Heinz Ludwig ; Thierry Facon ; Roman Hajek ; Katja Weisel ; Vania Hungria ; Leonard Minuk ; Shibao Feng ; Anita Zahlten-Kumeli ; Amy S. Kimball ; Philippe Moreau | Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. |
| 000525 (2017) |
Harpreet S. Wasan ; Peter Gibbs ; Navesh K. Sharma ; Julien Taieb ; Volker Heinemann ; Jens Ricke ; Marc Peeters ; Michael Findlay ; Andrew Weaver ; Jamie Mills ; Charles Wilson ; Richard Adams ; Anne Francis ; Joanna Moschandreas ; Pradeep S. Virdee ; Peter Dutton ; Sharon Love ; Val Gebski ; Alastair Gray ; Guy Van Hazel ; Ricky A. Sharma | First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. |
| 000528 (2017) |
Benjamin Lacas ; Jean Bourhis ; Jens Overgaard ; Qiang Zhang ; Vincent Grégoire ; Matthew Nankivell ; Björn Zackrisson ; Zbigniew Szutkowski ; Rafał Suwi Ski ; Michael Poulsen ; Brian O'Sullivan ; Renzo Corv ; Sarbani Ghosh Laskar ; Carlo Fallai ; Hideya Yamazaki ; Werner Dobrowsky ; Kwan Ho Cho ; Adam S. Garden ; Johannes A. Langendijk ; Celia Maria Pais Viegas ; John Hay ; Mohamed Lotayef ; Mahesh K B. Parmar ; Anne Aupérin ; Carla Van Herpen ; Philippe Maingon ; Andy M. Trotti ; Cai Grau ; Jean-Pierre Pignon ; Pierre Blanchard | Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. |
| 000529 (2017) |
Eric Pujade-Lauraine ; Jonathan A. Ledermann ; Frédéric Selle ; Val Gebski ; Richard T. Penson ; Amit M. Oza ; Jacob Korach ; Tomasz Huzarski ; Andrés Poveda ; Sandro Pignata ; Michael Friedlander ; Nicoletta Colombo ; Philipp Harter ; Keiichi Fujiwara ; Isabelle Ray-Coquard ; Susana Banerjee ; Joyce Liu ; Elizabeth S. Lowe ; Ralph Bloomfield ; Patricia Pautier | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. |
| 000531 (2017) |
Michael J. Overman ; Ray Mcdermott ; Joseph L. Leach ; Sara Lonardi ; Heinz-Josef Lenz ; Michael A. Morse ; Jayesh Desai ; Andrew Hill ; Michael Axelson ; Rebecca A. Moss ; Monica V. Goldberg ; Z Alexander Cao ; Jean-Marie Ledeine ; Gregory A. Maglinte ; Scott Kopetz ; Thierry André | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. |
| 000534 (2017) |
Michele Maio ; Arnaud Scherpereel ; Luana Calabr ; Joachim Aerts ; Susana Cedres Perez ; Alessandra Bearz ; Kristiaan Nackaerts ; Dean A. Fennell ; Dariusz Kowalski ; Anne S. Tsao ; Paul Taylor ; Federica Grosso ; Scott J. Antonia ; Anna K. Nowak ; Maria Taboada ; Martina Puglisi ; Paul K. Stockman ; Hedy L. Kindler | Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. |
| 000610 (2017) |
Michael A. Davies ; Philippe Saiag ; Georgina V. Long | Primary medical therapy for BRAF(V600E)-mutant melanoma brain metastases-is this good enough? - Authors' reply. |
| 000630 (2017) |
Benjamin O. Wolthers ; Thomas L. Frandsen ; André Baruchel ; Andishe Attarbaschi ; Shlomit Barzilai ; Antonella Colombini ; Gabriele Escherich ; Kathrine Grell ; Hiroto Inaba ; Gábor Kovacs ; Der-Cherng Liang ; Marion Mateos ; Veerle Mondelaers ; Anja Möricke ; Tomasz Ociepa ; Sujith Samarasinghe ; Lewis B. Silverman ; Inge M. Van Der Sluis ; Martin Stanulla ; Lynda M. Vrooman ; Michihiro Yano ; Ester Zapotocka ; Kjeld Schmiegelow | Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. |
| 000975 (2017) |
Michael A. Davies ; Philippe Saiag ; Caroline Robert ; Jean-Jacques Grob ; Keith T. Flaherty ; Ana Arance ; Vanna Chiarion-Sileni ; Luc Thomas ; Thierry Lesimple ; Laurent Mortier ; Stergios J. Moschos ; David Hogg ; Iván Márquez-Rodas ; Michele Del Vecchio ; Céleste Lebbé ; Nicolas Meyer ; Ying Zhang ; Yingjie Huang ; Bijoyesh Mookerjee ; Georgina V. Long | Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. |
| 000D14 (2017) |
Paolo A. Ascierto ; Michele Del Vecchio ; Caroline Robert ; Andrzej Mackiewicz ; Vanna Chiarion-Sileni ; Ana Arance ; Céleste Lebbé ; Lars Bastholt ; Omid Hamid ; Piotr Rutkowski ; Catriona Mcneil ; Claus Garbe ; Carmen Loquai ; Brigitte Dreno ; Luc Thomas ; Jean-Jacques Grob ; Gabriella Liszkay ; Marta Nyakas ; Ralf Gutzmer ; Joanna Pikiel ; Florent Grange ; Christoph Hoeller ; Virginia Ferraresi ; Michael Smylie ; Dirk Schadendorf ; Laurent Mortier ; Inge Marie Svane ; Delphine Hennicken ; Anila Qureshi ; Michele Maio | Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. |
| 000E58 (2017) |
Reinhard Dummer ; Dirk Schadendorf ; Paolo A. Ascierto ; Ana Arance ; Caroline Dutriaux ; Anna Maria Di Giacomo ; Piotr Rutkowski ; Michele Del Vecchio ; Ralf Gutzmer ; Mario Mandala ; Luc Thomas ; Lev Demidov ; Claus Garbe ; David Hogg ; Gabriella Liszkay ; Paola Queirolo ; Ernesto Wasserman ; James Ford ; Marine Weill ; L Andres Sirulnik ; Valentine Jehl ; Viviana Boz N ; Georgina V. Long ; Keith Flaherty | Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. |
| 000E64 (2017) |
Ruth Ladenstein ; Ulrike Pötschger ; Andrew D J. Pearson ; Penelope Brock ; Roberto Luksch ; Victoria Castel ; Isaac Yaniv ; Vassilios Papadakis ; Geneviève Laureys ; Josef Malis ; Walentyna Balwierz ; Ellen Ruud ; Per Kogner ; Henrik Schroeder ; Ana Forjaz De Lacerda ; Maja Beck-Popovic ; Pavel Bician ; Mikl S Garami ; Toby Trahair ; Adela Canete ; Peter F. Ambros ; Keith Holmes ; Mark Gaze ; Günter Schreier ; Alberto Garaventa ; Gilles Vassal ; Jean Michon ; Dominique Valteau-Couanet | Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. |
| 001023 (2017) |
Andrew D. Zelenetz ; Jacqueline C. Barrientos ; Jennifer R. Brown ; Bertrand Coiffier ; Julio Delgado ; Mikl S Egyed ; Paolo Ghia ; Árpád Illés ; Wojciech Jurczak ; Paula Marlton ; Marco Montillo ; Franck Morschhauser ; Alexander S. Pristupa ; Tadeusz Robak ; Jeff P. Sharman ; David Simpson ; Lukáš Smolej ; Eugen Tausch ; Adeboye H. Adewoye ; Lyndah K. Dreiling ; Yeonhee Kim ; Stephan Stilgenbauer ; Peter Hillmen | Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. |
| 001158 (2017) |
Meletios A. Dimopoulos ; Judith Trotman ; Alessandra Tedeschi ; Jeffrey V. Matous ; David Macdonald ; Constantine Tam ; Olivier Tournilhac ; Shuo Ma ; Albert Oriol ; Leonard T. Heffner ; Chaim Shustik ; Ram N García-Sanz ; Robert F. Cornell ; Carlos Fernández De Larrea ; Jorge J. Castillo ; Miquel Granell ; Marie-Christine Kyrtsonis ; Veronique Leblond ; Argiris Symeonidis ; Efstathios Kastritis ; Priyanka Singh ; Jianling Li ; Thorsten Graef ; Elizabeth Bilotti ; Steven Treon ; Christian Buske | Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. |
| 001243 (2017) |
Elizabeth M. Swisher ; Kevin K. Lin ; Amit M. Oza ; Clare L. Scott ; Heidi Giordano ; James Sun ; Gottfried E. Konecny ; Robert L. Coleman ; Anna V. Tinker ; David M. O'Malley ; Rebecca S. Kristeleit ; Ling Ma ; Katherine M. Bell-Mcguinn ; James D. Brenton ; Janiel M. Cragun ; Ana Oaknin ; Isabelle Ray-Coquard ; Maria I. Harrell ; Elaina Mann ; Scott H. Kaufmann ; Anne Floquet ; Alexandra Leary ; Thomas C. Harding ; Sandra Goble ; Lara Maloney ; Jeff Isaacson ; Andrew R. Allen ; Lindsey Rolfe ; Roman Yelensky ; Mitch Raponi ; Iain A. Mcneish | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. |
| 001339 (2017) |
Stephen J. Luen ; Roberto Salgado ; Stephen Fox ; Peter Savas ; Jennifer Eng-Wong ; Emma Clark ; Astrid Kiermaier ; Sandra M. Swain ; Jose Baselga ; Stefan Michiels ; Sherene Loi | Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. |
| 001501 (2016) |
Georgina V. Long ; Jean-Jacques Grob ; Paul Nathan ; Antoni Ribas ; Caroline Robert ; Dirk Schadendorf ; Stephen R. Lane ; Carmen Mak ; Philippe Legenne ; Keith T. Flaherty ; Michael A. Davies | Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. |
| 001526 (2016) |
Jan Franko ; Qian Shi ; Jeffrey P. Meyers ; Timothy S. Maughan ; Richard A. Adams ; Matthew T. Seymour ; Leonard Saltz ; Cornelis J A. Punt ; Miriam Koopman ; Christophe Tournigand ; Niall C. Tebbutt ; Eduardo Diaz-Rubio ; John Souglakos ; Alfredo Falcone ; Benoist Chibaudel ; Volker Heinemann ; Joseph Moen ; Aimery De Gramont ; Daniel J. Sargent ; Axel Grothey | Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. |
| 001593 (2016) |
Andrew Bottomley ; Madeline Pe ; Jeff Sloan ; Ethan Basch ; Franck Bonnetain ; Melanie Calvert ; Alicyn Campbell ; Charles Cleeland ; Kim Cocks ; Laurence Collette ; Amylou C. Dueck ; Nancy Devlin ; Hans-Henning Flechtner ; Carolyn Gotay ; Eva Greimel ; Ingolf Griebsch ; Mogens Groenvold ; Jean-Francois Hamel ; Madeleine King ; Paul G. Kluetz ; Michael Koller ; Daniel C. Malone ; Francesca Martinelli ; Sandra A. Mitchell ; Carol M. Moinpour ; Jammbe Musoro ; Daniel O'Connor ; Kathy Oliver ; Elisabeth Piault-Louis ; Martine Piccart ; Francisco L. Pimentel ; Chantal Quinten ; Jaap C. Reijneveld ; Christoph Schürmann ; Ashley Wilder Smith ; Katherine M. Soltys ; Martin J B. Taphoorn ; Galina Velikova ; Corneel Coens | Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. |
